Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

Source:http://linkedlifedata.com/resource/pubmed/id/16166447

Clin. Cancer Res. 2005 Sep 15 11 18 6678-85

Download in:

View as

Triples

General Info

PMID
16166447